Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform.

ABSTRACT:

Purpose

Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in early breast cancer (EBC) is largely dependent on breast cancer subtype, but no clinical-grade model exists to predict response and guide selection of treatment. A biophysical simulation of response to NAC has the potential to address this unmet need.

Methods

We conducted a retrospective evaluation of a biophysical simulation model as a predictor of pCR. Patients who received standard NAC at the University of Chicago for EBC between January 1st, 2010 and March 31st, 2020 were included. Response was predicted using baseline breast MRI, clinicopathologic features, and treatment regimen by investigators who were blinded to patient outcomes.

Results

A total of 144 tumors from 141 patients were

SUBMITTER: Howard FM 

PROVIDER: S-EPMC9550684 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature